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Abstract: Idiopathic Pulmonary fibrosis (IPF) is a catastrophic disease with poor outcomes and
limited pharmacological approaches. Heat shock protein 90 (HSP90) has been recently involved
in the wound-healing pathological response that leads to collagen deposition in patients with IPF
and its inhibition represents an exciting drug target against the development of pulmonary fibrosis.
Under physiological conditions, HSP90 guarantees proteostasis through the refolding of damaged
proteins and the degradation of irreversibly damaged ones. Additionally, its inhibition, by specific
HSP90 inhibitors (e.g., 17 AAG, 17 DAG, and AUY-922) has proven beneficial in different preclinical
models of human disease. HSP90 inhibition modulates a complex subset of kinases and interferes
with intracellular signaling pathways and proteome regulation. In this review, we evaluated the
current evidence and rationale for the use of HSP90 inhibitors in the treatment of pulmonary fibrosis,
discussed the intracellular pathways involved, described the limitations of the current understanding
and provided insights for future research.
Keywords: Idiopathic Pulmonary Fibrosis; HSP90; HSP90 inhibitor; AUY-922; 17 AAG; Proteome;
Proteomics; ERK; TGF-β; HSPome
1. Introduction
Idiopathic Pulmonary Fibrosis (IPF) is a devastating disease, characterized by the progressive
substitution of the lung parenchyma with a fibrotic scar. It is associated with poor prognosis and
an estimated mean survival of 2–5 years from the time of diagnosis [1]. The pathophysiology
of IPF is not completely understood; hypotheses for the principal causes of IPF include genetic
predisposition, exaggerated immune response with fibroblast activation [2] and a defective mechanism
in the wound-healing response to alveolar cell injury [3]. There are only two FDA-approved drugs
for the treatment of IPF—Pirfenidone and Nintedanib [4]. Neither stops nor reverses the disease,
but both slow disease progression and extend survival [5,6]. As of today, a cure is still missing
and due to increasing trends in mortality over the last decades [7,8], there is an urgent need for the
development of new pharmacological approaches capable of blocking disease progression and even
restoring normal lung parenchyma. Proteomic studies have focused in identifying new biomarkers
and the molecular pathology of IPF, utilizing peripheral blood, Bronchoalveolar Lavage Fluid (BALF)
or parenchymal biopsies.
Int. J. Mol. Sci. 2020, 21, 5286; doi:10.3390/ijms21155286 www.mdpi.com/journal/ijms
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Heat shock proteins (HSPs) constitute a large family of co-chaperones classified by molecular
weight and involved in the correct folding of a large number of “client proteins”. HSPs react to heat,
hypoxia and oxidative stress, by assisting the assembly, stabilization, and translocation of oligomeric
proteins [9]. Furthermore, when proteins are irreversibly damaged, HSPs promote their proteasomal
degradation, avoiding the accumulation of deformed proteins in the cytoplasm [10]. The maintenance
of a proper protein homeostasis (proteostasis) is crucial for cell survival, and is regulated by a
complex and heterogeneous proteostasis network [11]. Through the refolding of misfolded proteins,
segmentation of aggregated proteins and degradation of abnormal proteins, HSPs represent a crucial
sophisticated machinery, which is activated by stress to preserve cell proteostasis [9,12,13]. While under
physiological condition, HSPs act as guardians of the Proteome [14], their role in some diseases is
uncertain. Pharmacological interventions that interfere within the HSP network have shown beneficial
effects in cancer [15], neurodegenerative [16], and inflammatory diseases [17,18]. The rationale for
these interventions is based on observations that persistent inflammation and damage to DNA can
lead to abnormal activation of HSPs which could play a role in the pathophysiological mechanism of
cell injury and disease progression.
HSP90, the most abundant of HSPs, is increased in patients with IPF [19] and has recently been
investigated as a possible therapeutical target [20]. In this case, HSPs’ activation (phosphorylation) is
suspected to be a pathological step that, activated by inflammation [21], promotes the synthesis and
production of extracellular matrix and collagen. Accordingly, HSP90 inhibition represents an exciting
approach that is collecting promising data in pre-clinical studies. Specifically, inhibition of HSP90 is
considered effective in blocking the signaling pathway of Transforming Growth Factor-β (TGF- β),
a crucial overexpressed profibrotic cytokine in Pulmonary Fibrosis (PF) (Figure 1) [22].
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Figure 1. Heat shock protein 90 (HSP90) plays a role in the pro-fibrotic process in the lung that
follows an inflammatory stimulus. Furthermore, it is involved in TGF-β signali g, fibroblast activation,
and depositi n of collagen.
It is important to understand, however, that HSP90 interacts with a great number of proteins,
kinase , and tr scription factors and that i s inhibition is followed by a strong odulation of the
prot ome and phos h prote me, a large part of which is n t completely understood. From this
perspective, proteomic analysis of IPF rep esents one of the most promising methodologies in
defining unkn wn pathw ys of IPF pathogenesis and in revealing how HSP90 inhibiti n may affect
these pathways.
The aim of this review is to discuss the current understanding of HSP90′s role in the development
of pulmonary fibrosis, the current proteomic understanding of IPF, evaluate available preclinical data
and describe how inhibition of HSP90 co ld be a therapeutical target for patients with IPF.
2. Heat Shock Protein 90 Structure
HSP90 is one of the most expressed heat shock proteins, found in both bacteria and eukaryotes [23].
It plays an important role in the stress response to environmental insults (heat, hypoxia, and oxidative
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stress) as it mediates the correct folding and stabilization of several proteins, guaranteeing their function
and promoting cell survival. HSP90 is a highly conserved ATP-dependent molecule composed by
an N-Terminal ATP-binding Domain (NTD), a middle domain (MD), and a C-Terminal dimerization
Domain (CTD). N- and M- domains are connected via a flexible linker of over 60 residues in length,
which is important for HSP90 eukaryotic function, but is absent in bacterial and mitochondrial isoforms
(Figure 2) [24].
Int. J. Mol. Sci. 2020, 21, x 3 of 15 
 
composed by an N-Termi al ATP-binding Do ain (NTD),  middle domain (MD), and a C-Term nal 
di erization Dom in (CTD). N- and M- domains re connected via a fl xible linker of over 60 
residues in length, which is important for HSP90 eukaryotic function, but is absent i  bacterial and 
mitochondrial isoforms (Figure 2) [24]. 
 
Figure 2. Primary structure of the yeast HSP90. The N-Terminal-Domain (NTD-red) is a highly 
conserved domain among HSPs and contains the ATP-binding pocket, target of many HSP90 
inhibitors. The Middle-Domain (MD-green) is divided into three regions (a 3-layer α–β–α sandwich, 
a 3-turn α-helix and irregular loops and a 6-turn α-helix) and it is involved in client and substrate 
binding that increase ATPase activity (Aha1, Hch1). The C-terminal Domain (CTD-blue) possesses a 
moderate alternative ATP-binding site that become available when the N-terminal pocket is occupied. 
The NTD is conserved among HSPs and shares homology with the ATPase/kinase GHKL 
(Gyrase, HSP90, Histidine Kinase, MutL) superfamily [25]. It presents an ATP-binding site which is 
15 Å (1.5 nm) deep and cleaves ATP into ADP + P. This region is the principal binding site of HSP0 
inhibitors (e.g., geldanamycin and radicicol) and currently under intense study for its therapeutic 
implications [26]. The MD is made up of three regions: a three-layer α-β-α sandwich, a three-turn α-
helix with irregular loops and a six-turn α-helix. It has been suggested that the binding to Aha1, in a 
highly conserved tyrosine (Y313 of Hsp90α) of the MD, is responsible for the regulation of the 
conformational changes of HSP90, that modulate its intrinsic hydroxylating activity [27]. 
Accordingly, the enzymatic activity of HSP90 is also related to Arg-32, a key coupling element 
responsible for communication across HSP90 domains [28]. The third domain, the CTD interacts with 
co-chaperones like cyclophilin-40, PP5, stress-induced phosphoprotein 1 (Sti/Hop) and 
immunophilins FKBP51-52 through a tetracopeptide repeat (TPR) motif recognition site expressed at 
the end of the domain [29]. 
HSP90 chaperones form homodimers through the binding of the N-domain acquiring a V shape-
dimer with ATP-depending conformational shifts [30]. This complex, in the ATP-bound state 
assumes a closed N-terminal domain, whose mechanism has not been completely understood [31]. 
However, it is clear that when HSP90 is phosphorylated it assumes a stronger chaperone activity, 
required during stress situations. The inhibitors, which have showed much higher affinity for the 
phosphorylated and pathological isoforms of HSP90 [32,33], bind the ATP-binding site of the NTD 
preventing ATP hydrolysis and reducing HSP90 chaperone activity [34]. It is important to note that 
Figure 2. Primary structure of the yeast HSP90. The N-Terminal-Domain (NTD-red) is a highly
conserved domain among HSPs and contains the ATP-binding pocket, target of many HSP90 inhibitors.
The Middle-Domain (MD-green) is divided into three regions (a 3-layer α–β–α sandwich, a 3-turn
α-helix and irregular loops and a 6-turn α-helix) and it is involved in client and substrate binding
that increase ATPase activity (Aha1, Hch1). The C-terminal Domain (CTD-blue) possesses a moderate
alternative ATP-binding site that become available when the N-terminal pocket is occupied.
The NTD is conserved among HSPs and shares homology with the ATPase/kinase GHKL (Gyrase,
HSP90, Histidine Kinase, MutL) superfamily [25]. It presents an ATP-binding site which is 15 Å (1.5 nm)
deep and cleaves ATP into ADP + P. This region is the principal binding site of HSP0 inhibitors (e.g.,
geldanamycin and radicicol) and currently under intense study for its therapeutic implications [26].
The MD is made up of three regions: a three-layer α-β-α sandwich, a three-turn α-helix with irregular
loops and a six-turn α-helix. It has been suggested that the binding to Aha1, in a highly conserved
tyrosine (Y313 of Hsp90α) of the MD, is responsible for the regulation of the conformational changes
of HSP90, that modulate its intrinsic hydroxylating activity [27]. Accordingly, the enzymatic activity
of HSP90 is also related to Arg-32, a key coupling element responsible for communication across
HSP90 domains [28]. The third domain, the CTD interacts with co-chaperones like cyclophilin-40, PP5,
stress-induced phosphoprotein 1 (Sti/Hop) and immunophilins FKBP51-52 through a tetracopeptide
repeat (TPR) motif recognition site expressed at the end of the domain [29].
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phosphorylated and pathological isoforms of HSP90 [32,33], bind the ATP-binding site of the NTD
preventing ATP hydrolysis and reducing HSP90 chaperone activity [34]. It is important to note that the
C-terminal domain of HSP90 presents an alternative ATP-binding pocket, which guarantees a minimal
chaperone activity when the N-terminal binding pocket is occupied or inhibited [35].
3. HSP90 “Guardian” of the Proteome
HSPs represent a sophisticated protein quality-control network, which assist protein folding
during assembly, and selectively degrade irreversibly damaged proteins. HSP90, the most studied
and abundant of HSPs, is crucial for maturation of signaling proteins involved in cell division and
development, such as steroid hormone receptors, kinases and key oncogenic proteins like the tumor
suppressor p53 [36,37]. HSP90, together with HSP70 and other co-chaperones, promote the late-stage
folding and maturation of more than 400 client proteins [37], including kinases, transcription factors,
and E3 ubiquitin ligase [38]. In an attempt to define the human substrates that interact with HSP90,
Lindquist et al. carried a quantitative analysis of HSP90-interactions and discovered that HSP90 forms
complexes with 60% of human kinases, 30% of ubiquitin ligases, and ~7% of transcriptional factors [38].
The large number of interactions with the kinome appears to be dependent on HSP90′s cochaperone
CDC37, as shown by the reduction in HSP90/kinase complex formation after CDC37 knockdown and,
at the same time, suggesting CDC37 as a highly specialized cochaperone adaptor for kinases [39,40].
Upon HSP90 inhibition, HSP90-client kinases are redirected through degradation or accumulation.
Professor Didier Picard greatly contributed to the overall understanding of the HSP90 interactome,
collecting the results of different studies and creating an online platform to help researcher in the
general understanding of this complex network (www.hsp90.org [41]). However, as HSP90 not only
regulates the proper function of several proteins but also modulates transcriptional factor, the definition
of the pathways affected by HSP90 modulation are challenging and complex to define.
During stress, the Heat Shock Response (HSR) regulates the cytoplasmic proteostasis response,
through the transcription of stress genes and the de novo synthesis of heat shock proteins in order
to guarantee cell survival, adaptation to circulating hormones and protection of proteins from
environmental insults [42,43]. Besides, HSPs direct, through HSP90′s leading role, a cytoprotective
effect on cells, if cells are exposed to persistent inflammation and DNA damage, HSP90 could promote
the exaggerate downstream signaling of inflammation promoting cell transformation and endorsing
the folding of a tremendous amount of stress proteins, which end up accumulating.
The “HSPome”, defined as the part of the proteome affected by HSPs activity and modulation, as we
previously mentioned, is constituted by an enormous number of functional proteins, transcriptional
factors and ubiquitinases, whose expression could be regulated by the use of inhibitors resulting in
profound changes in cell morphology and functionality, especially in response to stress.
In cancer, HSP90 regulates a high number of proteins involved in cellular signaling and tumor
promotion, making HSP90 inhibitors a therapeutic approach with great potential [44]. Similarly,
due to the vast difference of IPF proteome and HSPome compared to controls, inhibition of HSP90 is a
promising intervention which could impede the profound changes in protein expression observed in
late stage of the disease.
4. Proteomic Analysis in Idiopathic Pulmonary Fibrosis
Current proteomic understanding of IPF is derived from peripheral blood, bronchoalveolar lavage
fluid (BALF), and lung tissue analysis. Patients with IPF exhibit variable rates of disease progression
and for this reason many studies have focused on finding new biomarkers or indicators of therapeutic
response to monitor these patients [45]. Proteomic profiling plays an important role in biomarker
discovery [46] and preliminary studies have shown how patients with IPF display a unique peripheral
blood proteome [47,48]. The IPF-PRO registry, a multicenter cohort study, analyzed over 1300 proteins
in peripheral blood of patients with IPF and compared them to healthy controls, identifying nine
proteins that accurately distinguished patients with IPF from controls. The circulating proteome
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differed for apolipoprotein A-1 (APOA1), complement C1r subcomponent, intracellular adhesion
molecule 5 (ICAM5), C-C motif chemokine 18, 14-3-3 protein sigma (SFN), sonic hedgehog protein,
oxidized low-density lipoprotein receptor 1, matrix metalloproteinase 3 (MMP3), macrophage-capping
protein, and heat shock protein 90 beta-1 (HSP90β1) [49] (Table 1).
Table 1. Proteomic analysis in studies on Idiopathic Pulmonary Fibrosis (IPF).
Study Species Sample Increased Expression
Todd et al. [49] Human Peripheral blood
APOA1, complement C1r subcomponent, ICAM5, CC-motif
chemokine 18, 14-3-3 SFN, sonic hedgehog protein, Oxidized
low density lipoprotein. Receptor 1, MMP3, macrophage
capping protein, HSP90β-1.
Foster et al. [50] Human BALF Eosinophil cationic protein, eosinophil lysophospholipase,MMP8, osteopontin, CC-motif chemokine 18 and collagens.
Carleo et al. [51] Human BALF
Polymeric immunoglobulin receptors, α-1-B-glycoprotein,
fibrinogen-γ, α-1-antitrypsin, complement C3, isocitrate,
dehydrogenase, peroxiredoxin 1, ceruloplasmin,
serotransferrin, SPA2 and hemopexin.
Ohlmeier et al. [52] Human BALF esRAGE
Tian et al. [53] Human Lung Collagen 1, cathepsin B, AGR-2, galectin-7, HSP90α, HSP90β
Landi et al. [54] Human Lung Alpha-1-antitripsin, SEPRINA3, GSTP1, 14-3-3, HSF-1,NF-AT4, C-Myc
Korfei et al. [55] Human Lung HSP90α, HSP90β, HSP60
Schiller et al. [56] mice Lung Emylin-2, Collagen-XXVIII, Wnt1
Summarized data from different proteomic studies on IPF. APOA1: Apolipoprotein A-1, ICAM-5: intracellular
adhesion molecule 5; SFN 14-3-3 protein Sigma; MMP3: Matrix MetalloProteinase 3; HSP90β-1: Heat Shock Protein
90β-1; MMP8: Matrix MetalloProteinase 8; SPA2: Surfactant Associated Protein A2; esRAGE: endogenous soluble
form of Receptor for Advanced Glycation End-products; AGR-2: Anterior Gradient Protein 2; HSP90α: Heat Shock
Protein α; SEPRINA3: alpha-1-antychymotripsin; GSTP1: Glutathione S Transferase P1; HSF-1: Heat Shock Factor 1;
NF-AT4: Nuclear Factor of Activated T cell.
Even though the profile of circulating proteins differs from lung proteins, it can still provide insight
into biological pathways linked to a persistent overexpression of inflammatory markers, adhesion
molecules, complement proteins and HSPs.
BALF proteomic analysis of patients with IPF, compared to matched healthy controls, displayed
an increased number of eosinophil and neutrophil proteins (eosinophil cationic protein, eosinophil
lysophospholipase, and metalloproteinase 8 (MMP8)), profibrotic cytokines (osteopontin, C-C motif
chemokine 18 (CCL19), and various collagens [50]. Carleo et al. compared BALF of familial
IPF vs. sporadic IPF, highlighting different protein patterns in immune response (polymeric
immunoglobulin receptors, and α-1-B-glycoprotein), coagulation (fibrinogen-γ, α1-antitrypsin,
complement C3), wound response, oxidative stress (isocitrate, dehydrogenase, and peroxiredoxin 1) and
ion homeostasis (ceruloplasmin, serotransferrin, and hemopexin) [51]. Furthermore, their findings on
surfactant-associated protein A2 (SPA2) supported the IPF pathogenic theory of unresolved endoplasmic
reticulum (ER) stress, SFTPA2 isoform mutation and accumulation, proteostasis disturbance and
prolonged Unfolded Protein Response (UPR) signaling leading to type 2 alveolar-epithelial cells
(AECII) apoptosis or senescence [57–59].
Furthermore, isoforms of Receptor for Advanced Glycation End-products (RAGE)—whose activity
is related to activation of kinases (MAPK) and transcriptional factors (NF-κB) [60]—were analyzed
in the BALF of IPF, COPD, and healthy subjects and revealed that RAGE (especially the endogenous
soluble form (esRAGE)) is an important pro-fibrotic marker [52].
Isobaric tag for relative and absolute quantitation (iTRAQ) combined with liquid
chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze proteomic changes in
lung tissue of IPF patients and controls [53]. From more than 4000 proteins analyzed, 600 were founded
altered (455 upregulated and 207 downregulated) confirming previous results on extracellular matrix
overexpression and defining new involved proteins. Among these, several collagens, glycoproteins,
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proteoglycans, and secretory and regulatory factor matrisomes were identified and validated by Western
blotting, confirming the role of collagen 1, cathepsin B, AGR-2, galectin-7, HSP90α, and HSP90β [53].
In another study, functional proteomics was used to analyze differences in four diseases (idiopathic
pulmonary fibrosis, sarcoidosis, systemic sclerosis, and pulmonary Langerhans sclerosis). A network
was observed linking alpha-1-antitrypsin, alpha-1-antychymotripsin (SEPRINA3), glutathione S
transferase P1 (GSTP1) to 14-3-3 epsilon, its regulatory action on transcription factors, including heat
shock factor 1 (HSF-1), NF-AT4, and C-myc, as well as inhibition of protein kinases [54].
In a murine model of bleomycin-induced PF, the proteome and secretome were studied at different
time points in order to define fibrotic and regenerative stages [56]. Two unexpected proteins showed a
significant increase in the fibrotic stage—Emilin-2 and Collagen-XXVIII—which were incorporated
in the extracellular matrix (ECM) matrix and in the peribronchial and perivascular layers. A group
of extracellular niche proteins and laminins were also identified which reacted to injury and whose
expression is usually restricted to embryonic development. Emilin-2 was believed to bind Wnt1 in
the extracellular space and promote the alveolar extrinsic apoptotic pathway [61]. Differently, in the
recovery phase, Nrf2—a reactive oxygen species (ROS) transcriptional factor- increased at day 14 and
28, accompanying the recovery phase of bleomycin-induced fibrosis, as previously suggested [62].
Finally, proteomic study of IPF lungs and controls revealed a profound upregulation of HSPs including
HSP90α, HSP90β, and mitochondrial HSP60, whose expression was associated with their role in the
UPR and the activation of mitochondrial apoptosis pathways [55].
Taken together, these data strongly suggest that IPF could be classified as a disease with
“unbalanced” proteostasis, whose main affected proteins could function as new biomarkers for disease
severity. This data also indicates that HSP90 should be considered as a potential target for new
therapeutic approaches.
5. HSP90 Pathways in Pulmonary Fibrosis
There is a rising amount of literature suggesting that HSP90 plays an important role in
fibrogenesis [63] and that the observed high levels of HSP90 represent a pathological step required for
disease progression (Table 2). IPF patients display high levels of HSP90 in plasma, whose expression
is correlated with IPF severity, and fibroblast of patients with IPF secrete an increased amount of
HSP90 [64]. Immunohistochemistry studies revealed the presence of both HSP90α and HSP90β in the
pulmonary interstitium of IPF lungs with increased expression in myofibroblasts and fibroblast foci of
IPF samples, compared to controls. Similarly, Western blot analysis showed significant upregulation
of HSP90β in cultured Interstitial Lung Fibroblasts (ILFBs) from patients with IPF compared to
controls [65]. Mechanical stretch of rat fibrotic lungs ex vivo provoked the release of HSP90 in the
BALF [64].
HSP90α is able to promote the phosphorylation of Protein kinase B (AKT) in Thr308, P38,
and extracellular signal–regulated kinase (ERK) signaling pathways, which are known downstream
non-Smad-pathways of TGFβ1 signaling and participate in the development of pulmonary fibrosis [66].
Indeed, HSP90 has been shown to regulate ERK directly via dissociation of the ERK-HSP90-CDC37
complex [70] and indirectly by negatively inhibiting Raf metabolism and its downstream cascade [71].
Furthermore, HSP90 plays a critical role in TGFβ function by stabilizing its signaling cascade and
receptors [63,72]. At the same time HSP90 regulates nuclear localization of Smad, influencing and
modulating the Smad-dependent signaling cascade of TGF-β [73]. TGF-β, the leading cytokine in
IPF, is responsible for the epithelial-to-mesenchymal transformation (EMT) of epithelial cells into a
myofibroblastic phenotype that is related to the transformation of lung structure and the production
of extracellular matrix (ECM) [74], thus, interference with its complex signaling cascade represents
a reasonable therapeutic approach for IPF, supported by a strong mechanistic rationale. Changes
in lungs parenchymal architecture are among the most obvious pathological signs of pulmonary
fibrosis. Typical changes include diffuse alveolar edema and septal thickening, type II pneumocytes
hyperplasia, damage to lung structure and accumulation of airspace fibrin and collagen [75,76]. HSP90
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is overexpressed in lungs from IPF patients and high-magnification micrographs show that HSP90
is localized in both the cytosol and nucleus of fibroblasts [19]. Additionally, in a preliminary study,
we observed increased HSP90 immunoreactivity in pneumocytes, airway epithelium, and fibroblast
foci in areas of active fibrosis in rabbits with chemical-induced PF (Figure 3).
Table 2. Expression levels of HSP90 and its isoforms in clinical and preclinical studies of IPF.
Study Species Etiology Isoforms Sample Fold-Change
Korfei et al. [55] Human IPF HSP90 α Lung >2.3
HSP90 β Lung >4.8
Sontake et al. [19] Human IPF HSP90 Lung >1.5
Sibinska et al. [65] Human IPF HSP90 α Lung >1.5
Human IPF HSP90 β Lung >2.3
mice Bleomycin HSP90 α Lung >2.0
mice Bleomycin HSP90 β Lung >2.5
Hangming et al. [66] mice Bleomycin HSP90 α BALF >9
serum >1.8
Bellaye et al. [67] Human IPF HSP90 α serum >2.0
Human IPF HSP90 β serum no change
rat Mechanical stretch eHSP90 tissue increased
mice Mechanical stretch HSP90 BALF increased
Marinova et al. [68] mice Hydrochloric acid P-HSP90 Lung >2.1
Solopov et al. [69] mice Nitrogen Mustard P-HSP90 Lung >2.0
Table 2 collates significant evidence from different clinical and preclinical studies of IPF, were HSP90 was found
increased (fold-change expression levels) compared to healthy controls (p < 0.05). IPF: Idiopathic pulmonary fibrosis;
HSP90: Heat shock Protein 90; P-HSP90: Phosphorylated Heat Shock Protein 90; eHSP90—extracellular Heat Shock
Protein 90.
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and perivascular collagen deposition. (B) HSP90β immunohistostaining of the same section 
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Figure 3. Sections from rabbit lungs 60 days after intratracheal instillation of 0.1 N–hydrochloric acid.
(A) Masson’s Trichrome staining depicting fibrotic lesions, loss of alveolar architecture, peribronchial,
and perivascular collagen deposition. (B) HSP90β immunohistostaining of the same section displaying
upregulation of HSP90β (in brown) within the fibrotic tissue and in peribronchial regions.
Strong expression of both HSP90α and HSP90β was observed in abnormal bronchiolar structures
overlying fibroblast foci, as well as in hyperplastic bronchioles of IPF lungs. Hyperplastic type-II
alveolar epithelial cells (AECII) near areas of dense fibrosis displayed robust immunostaining of
HSP90β in IPF lungs compared to healthy donors, whereas HSP90α was absent in AECII. Smooth
muscle cells located in the wall of bronchioles showed expression of HSP90α and α-SMA, but not of
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HSP90β [65]. Collagen type I secretion likely depends on the activity of HSP90 chaperones, even though
such chaperone cannot directly engage nascent collagen molecules, but in addition to promoting TGF-β
signaling, it could influence collagen-I secretion via interactions with cytosolic components of the
secretory pathway [77]. Taken together these data suggest how HSP90 is involved in TGF-β receptor
stabilization, its Smad-dependent and Smad-independent signaling cascade and could influence
Collagen I secretion, representing an interesting target of new anti-fibrotic therapies (Figure 4).
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SP90 has also been found increased in animal models of pulmonary fibrosis. In the
bleomycin-induced mouse model, BALF and serum displayed high levels of HSP90α and this increase
was related to fibrosis [66]. Activated HSP90, phospho-HSP90, was elevated in lung tissue of ice ith
hydrochloric acid (HCl)-induced pulmonary fibrosis at 10 and 30 days after acid instillation, compared
to controls [68]. HSP90 tyrosine phosphorylation induced by 3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors was reported to increase its association with endothelial nitric oxide (eNOS) [78],
a marker for pul onary hypertension and pulmonary fibrosis [79]. Similarly, we observed increased
levels of phospho-HSP90 in a murine model of nitrogen mustard-induced pulmonary fibrosis [69].
6. Modulation of HSP90 by Molecular Inhibitors
HSP90 inhibitors have shown already efficacious results in cancer [80] and infectious diseases [81],
in which their ability to decrease protein folding resulted in reduced virus assembly and decreased
tumor development. A precise intervention, such as by HSP90 inhibitors, modulates and reduces
protein trafficking and restores proteostasis by diminishing HSP90 chaperone activity.
HSP90 inhibitors strongly decrease HSP90 interactions with kinases [38]. Sharma et al. defined the
action of HSP90 inhibitors, 17-AAG and 17-DMAG, on the proteome and phosphoproteome, revealing
that the blockade of the chaperone leads to more downregulated than upregulated proteins. Specifically,
HSP90 inhibitors modulated ARAF, AKT, CDK4, MET, and PDK1 affecting principally protein kinase
activity, as 34% of kinases were reduced and only 6% of them were upregulated [82]. In fact, HSP90
client kinases undergo several rounds of release and binding which promote the functional stability of
C)C) C) TGF-~ 
TGF-~R 
Int. J. Mol. Sci. 2020, 21, 5286 9 of 15
folded proteins. However, when a HSP90 inhibitor is applied, HSP90′s ATPase activity is reduced
and the reloading of clients into the chaperone is diminished [83]. These precise intervention redirects
kinase clients into one of two paths: degradation or aggregation. Furthermore, HSP90 inhibition is
not limited only to depletion of the proteome and phosphoproteome but also to the loss of activity of
those signaling pathways formed by HSP90-dependent proteins [84]. This reduction cannot just be
considered as a proteomic difference but as a metabolic redirection whose effects strongly differ from
untreated cells. Schumacher et al. [85] showed how geldanamycin, a HSP90 inhibitor, downregulated
119 peptides, including integrin, estrogen receptor, MAPK, JAK/STAT, PPAR, and NF-κB as well as
other cell cycle-regulatory and ubiquitin-mediated pathways. Another HSP90 inhibitor, IPI-504—a
more water-soluble analog of geldanamycin—showed to redirect pancreatic cancer cell proteome from
cell growth, maintenance, and transport to cellular metabolism, organization, and biogenesis [86].
The use of HSP90 inhibitors was also studied in HS68 fibroblasts and SW480, U2OS, and A549 cancer
cells. The effect on the kinome, after HSP90 inhibitors application showed downregulation in 70%
kinases of Hs68 cells (144 quantified kinases), including MAPK and TGF-β signaling pathways [87].
1G6-D7, another HSP90α inhibitor, attenuated the severity of the fibrotic process in a murine model of
Bleomycin-induced pulmonary fibrosis by lowering the circulating levels of HSP90α [66]. NVP-AUY922,
a highly potent HSP90 inhibitor with improved bioavailability and aqueous solubility compared to first
generation HSP90 inhibitors [88], successfully inhibited both HSP90α and HSP90β with similar median
inhibition concentration (IC50) values [89]. It is widely known that the mitogen-activated protein kinase
(MAPK)/MAPK kinase (MEK)/extracellular signal–regulated kinase (ERK) signaling cascade is a major
pathway controlling cellular processes associated with fibrogenesis [90]. The expression of total MEK,
p-MEK, total ERK, and also the phosphorylation of EGFR, a typical HSP90 client protein was found to be
reduced by AUY-922 [91]. Our previous studies have shown that AUY922 can depress phosphorylation
of ERK, interfering with TGF-β signaling, thereby preventing the development of HCL and Nitrogen
Mustard-induced pulmonary fibrosis [21,92,93]. The use of HSP90 inhibitors regulates TGF-β receptor
stabilization, interferes with Smad and non-Smad (Raf, P-ERK) TGF-β signaling cascade, activates
transcription factors and therefore decreases epithelial-to-mesenchymal transformation (EMT) and
reduces production of pro-fibrotic mediators and ECM. Furthermore, as HSP90 inhibitors were shown
to modulate several MAP kinases involved in inflammation, cell proliferation and fibrogenesis, further
studies are needed to define in particular these pathways in IPF.
By modulating the HSPome, HSP90 inhibitors affect complex intracellular networks involved in
the development of pulmonary fibrosis and offer strong rationale as useful therapeutical interventions
directing cells through protein degradation.
7. Current Limitation and Future Research
IPF is complex disease with unclear mechanisms of pathogenesis. Proteomic analysis together
with genomic studies represent a promising approach towards defining unknown pathways of genetic
predisposition and proteome unbalance in IPF. In recent years, several new molecules have been
implicated in its pathogenesis, creating new potential biomarkers and therapeutical targets. However,
it is important to note that every cell type presents its own proteome and some of the present data
arise from mixed cell populations. In order to characterize cell-to-cell differences, it would be ideal to
isolate either from BALF, lung tissue or peripheral blood each distinct cell type and carry its proteomic
evaluation. This would greatly contribute to a further description of the role that each cell, either
pneumocytes, endothelial or immune cells, play during the development of the disease.
Limitations also arise from the analysis of HSP90ome. HSP90 is involved in the stress response and
consequently expression and activity levels are affected by experimental and environmental conditions
that need to be considered when comparing different studies.
Further, HSP90 exists in multiple isoforms (e.g., α, β, αβ . . . ) that have a distinct role in cellular
metabolism, as some function in the cytosol, others in the nucleus, and others in the mitochondria,
thus establishing distinct interactive networks whose understanding is far from clear [94]. Notably,
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a large section of the current literature has only partially defined these differences and due to study
limitations, the understanding of HSP90′s nuclear isoforms is still limited.
Other disadvantages are related to the techniques used to study the relationship between HSP90
function and the proteome. Current technology is unable to distinguish between direct or indirect
interactions between the chaperone and other proteins. In addition, defining the client proteins
(HSPome) of HSP90 and how HSP90 inhibitors change their expression remains challenging. Large
proteomic analyses describe changes in proteins expressed in relatively high concentration while
HSP90 modulates many signaling and transcription factors which, are expressed at low levels in cells,
but are characterized by a strong metabolic activity.
Further issues arise when comparing the main proteomic studies on HSP90 inhibitors. Thus,
results from studies by Song [86], Maloney [95], Schumacher [85], and Sharma [82] differ significantly
among them, with just a few molecules identified in common. This suggest that HSP90 inhibitors
act differently on diverse cell lines, exerting unique cellular responses and underscoring again the
importance of a cell-specific proteomic evaluation in IPF.
Even though more studies are required, proteomic studies from IPF patients and laboratory
analysis of HSP90 inhibitors provide a strong mechanistic rationale for their investigation in IPF,
justifying further experimentation in preclinical studies to better identify their anti-fibrotic effects,
optimal dose strategy, and potential side effects.
8. Conclusions
IPF is a disease characterized by unbalance of the proteome. HSP90 plays an important role in the
pathogenesis of the fibrotic process in the lung. Controlled interventions, as with HSP90 inhibitors,
represent an exciting approach for the modulation of the proteome and phosphoproteome that has
been shown to result in reduction of pro-fibrotic markers, ECM proteins and improved lung mechanics
in several pre-clinical studies. Furthermore, HSP90 inhibitors critically interfere with Smad and
non-Smad intracellular signaling of TGF-β. As the modulation of HSP90 results in changes in multiple
pathways, further studies are necessary to define in detail how HSP90 inhibitors exert their beneficial
effect in IPF, the optimal dose strategy, and potential side effects.
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35. Sőti, C.; Racz, A.; Csermely, P. A Nucleotide-dependent Molecular Switch Controls ATP Binding at the
C-terminal Domain of Hsp90: N-TERMINAL NUCLEOTIDE BINDING UNMASKS A C-TERMINAL
BINDING POCKET. J. Biol. Chem. 2001, 277, 7066–7075. [CrossRef]
36. Saibil, H.R. Chaperone machines for protein folding, unfolding and disaggregation. Nat. Rev. Mol. Cell Biol.
2013, 14, 630–642. [CrossRef]
37. Pratt, W.B.; Toft, D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based
chaperone machinery. Exp. Biol. Med. 2003, 228, 111–133. [CrossRef]
38. Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover, K.D.; Karras, G.I.; Lindquist, S. Quantitative
Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition. Cell 2012, 150, 987–1001.
[CrossRef]
39. Grammatikakis, N.; Lin, J.-H.; Grammatikakis, A.; Tsichlis, P.N.; Cochran, B.H. p50cdc37 Acting in Concert
with Hsp90 Is Required for Raf-1 Function. Mol. Cell. Biol. 1999, 19, 1661–1672. [CrossRef]
40. Gray, P.J.; Prince, T.; Cheng, J.; Stevenson, M.A.; Calderwood, S.K. Targeting the oncogene and kinome
chaperone CDC37. Nat. Rev. Cancer 2008, 8, 491–495. [CrossRef]
41. Echeverria, P.C.; Bernthaler, A.; Dupuis, P.; Mayer, B.; Picard, D. An Interaction Network Predicted from
Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine. PLoS ONE 2011,
6, e26044. [CrossRef] [PubMed]
42. Westerheide, S.D.; Morimoto, R.I. Heat Shock Response Modulators as Therapeutic Tools for Diseases of
Protein Conformation. J. Boil. Chem. 2005, 280, 33097–33100. [CrossRef] [PubMed]
43. Chen, B.; Feder, M.E.; Kang, L. Evolution of heat-shock protein expression underlying adaptive responses to
environmental stress. Mol. Ecol. 2018, 27, 3040–3054. [CrossRef] [PubMed]
44. Neckers, L.M.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012,
18, 64–76. [CrossRef] [PubMed]
45. Vij, R.; Noth, I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl. Res. 2012, 159, 218–227.
[CrossRef]
46. Bowler, R.; Wendt, C.H.; Fessler, M.B.; Foster, M.W.; Kelly, R.S.; Lasky-Su, J.; Rogers, A.J.; Stringer, K.A.;
Winston, B.W. New Strategies and Challenges in Lung Proteomics and Metabolomics. An Official American
Thoracic Society Workshop Report. Ann. Am. Thorac. Soc. 2017, 14, 1721–1743. [CrossRef]
47. O’Dwyer, D.N.; Norman, K.C.; Xia, M.; Huang, Y.; Gurczynski, S.J.; Ashley, S.L.; White, E.S.; Flaherty, K.R.;
Martinez, F.J.; Murray, S.; et al. The peripheral blood proteome signature of idiopathic pulmonary fibrosis
is distinct from normal and is associated with novel immunological processes. Sci. Rep. 2017, 7, 46560.
[CrossRef]
48. Niu, R.; Liu, Y.; Zhang, Y.; Zhang, Y.; Wang, H.; Wang, Y.; Wang, W.; Li, X. iTRAQ-Based Proteomics Reveals
Novel Biomarkers for Idiopathic Pulmonary Fibrosis. PLoS ONE 2017, 12, e0170741. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 5286 13 of 15
49. Todd, J.L.; Neely, M.L.; Overton, R.; Durham, K.; Gulati, I.; Huang, H.; Roman, J.; Newby, L.K.; Flaherty, K.R.;
Vinisko, R.; et al. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the
multicentre IPF-PRO Registry. Respir. Res. 2019, 20, 227–313. [CrossRef]
50. Foster, M.W.; Morrison, L.D.; Todd, J.L.; Snyder, L.D.; Thompson, J.W.; Soderblom, E.J.; Plonk, K.;
Weinhold, K.J.; Townsend, R.; Minnich, A.; et al. Quantitative Proteomics of Bronchoalveolar Lavage
Fluid in Idiopathic Pulmonary Fibrosis. J. Proteome Res. 2015, 14, 1238–1249. [CrossRef]
51. Carleo, A.; Bargagli, E.; Landi, C.; Bennett, D.; Bianchi, L.; Gagliardi, A.; Carnemolla, C.; Perari, M.G.;
Cillis, G.; Armini, A.; et al. Comparative proteomic analysis of bronchoalveolar lavage of familial and
sporadic cases of idiopathic pulmonary fibrosis. J. Breath Res. 2016, 10, 26007. [CrossRef] [PubMed]
52. Ohlmeier, S.; Mazur, W.; Salmenkivi, K.; Myllärniemi, M.; Bergmann, U.; Kinnula, V.L. Proteomic studies
on receptor for advanced glycation end product variants in idiopathic pulmonary fibrosis and chronic
obstructive pulmonary disease. Proteom. Clin. Appl. 2010, 4, 97–105. [CrossRef] [PubMed]
53. Tian, Y.; Li, H.; Gao, Y.; Liu, C.; Qiu, T.; Wu, H.; Cao, M.; Zhang, Y.; Ding, H.; Chen, J.; et al. Quantitative
proteomic characterization of lung tissue in idiopathic pulmonary fibrosis. Clin. Proteom. 2019, 16, 1–11.
[CrossRef] [PubMed]
54. Landi, C.; Bargagli, E.; Bianchi, L.; Gagliardi, A.; Carleo, A.; Bennett, D.; Perari, M.; Armini, A.; Prasse, A.;
Rottoli, P.; et al. Towards a functional proteomics approach to the comprehension of idiopathic pulmonary
fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis. J. Proteom. 2013, 83,
60–75. [CrossRef] [PubMed]
55. Korfei, M.; Schmitt, S.; Ruppert, C.; Henneke, I.; Markart, P.; Loeh, B.; Mahavadi, P.; Wygrecka, M.;
Klepetko, W.; Fink, L.; et al. Comparative Proteomic Analysis of Lung Tissue from Patients with Idiopathic
Pulmonary Fibrosis (IPF) and Lung Transplant Donor Lungs. J. Proteome Res. 2011, 10, 2185–2205. [CrossRef]
[PubMed]
56. Schiller, H.B.; Fernandez, I.E.; Burgstaller, G.; Schaab, C.; Scheltema, R.A.; Schwarzmayr, T.; Strom, T.M.;
Eickelberg, O.; Mann, M. Time- and compartment-resolved proteome profiling of the extracellular niche in
lung injury and repair. Mol. Syst. Boil. 2015, 11, 819. [CrossRef] [PubMed]
57. Korfei, M.; Ruppert, C.; Mahavadi, P.; Henneke, I.; Markart, P.; Koch, M.; Lang, G.; Fink, L.; Bohle, R.-M.;
Seeger, W.; et al. Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary
Fibrosis. Am. J. Respir. Crit. Care Med. 2008, 178, 838–846. [CrossRef]
58. Korfei, M.; Von Der Beck, D.; Henneke, I.; Markart, P.; Ruppert, C.; Mahavadi, P.; Ghanim, B.; Klepetko, W.;
Fink, L.; Meiners, S.; et al. Comparative proteome analysis of lung tissue from patients with idiopathic
pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. J. Proteom. 2013, 85,
109–128. [CrossRef]
59. Lawson, W.E.; Cheng, N.-S.; Degryse, A.L.; Tanjore, H.; Polosukhin, V.V.; Xu, X.C.; Newcomb, D.C.; Jones, B.R.;
Roldan, J.; Lane, K.B.; et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc. Natl.
Acad. Sci. USA 2011, 108, 10562–10567. [CrossRef]
60. Bierhaus, A.; Humpert, P.M.; Morcos, M.; Wendt, T.; Chavakis, T.; Arnold, B.; Stern, D.M.; Nawroth, P.P.
Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 2005, 83, 876–886.
[CrossRef]
61. Mongiat, M.; Ligresti, G.; Marastoni, S.; Lorenzon, E.; Doliana, R.; Colombatti, A. Regulation of the Extrinsic
Apoptotic Pathway by the Extracellular Matrix Glycoprotein EMILIN2. Mol. Cell. Boil. 2007, 27, 7176–7187.
[CrossRef] [PubMed]
62. Hecker, L.; Logsdon, N.J.; Kurundkar, D.; Bernard, K.; Hock, T.; Meldrum, E.; Sanders, Y.Y.; Thannickal, V.J.;
Kurundkar, A. Reversal of Persistent Fibrosis in Aging by Targeting Nox4-Nrf2 Redox Imbalance.
Sci. Transl. Med. 2014, 6, 231ra47. [CrossRef] [PubMed]
63. Bellaye, P.-S.; Burgy, O.; Causse, S.; Garrido, C.; Bonniaud, P. Heat shock proteins in fibrosis and wound
healing: Good or evil? Pharmacol. Ther. 2014, 143, 119–132. [CrossRef] [PubMed]
64. Bellaye, P.-S.; Wheildon, N.; Shimbori, C.; Upagupta, C.; Kolb, M. Pathogenesis of Pulmonary Fibrosis -
The Role of Extracellular Heat Shock Protein-90 (HSP90) in Myofibroblast Differentiation and Persistence.
Qjm Int. J. Med. 2016, 4543. [CrossRef]
65. Sibinska, Z.; Tian, X.; Korfei, M.; Kojonazarov, B.; Kolb, J.S.; Klepetko, W.; Kosanovic, D.; Wygrecka, M.;
Ghofrani, H.A.; Weissmann, N.; et al. Amplified canonical transforming growth factor-β signalling via heat
shock protein 90 in pulmonary fibrosis. Eur. Respir. J. 2017, 49, 1501941. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 5286 14 of 15
66. Dong, H.; Luo, L.; Zou, M.; Huang, C.; Wan, X.; Hu, Y.; Le, Y.; Zhao, H.; Li, W.; Zou, F.; et al. Blockade
of extracellular heat shock protein 90α by 1G6-D7 attenuates pulmonary fibrosis through inhibiting ERK
signaling. Am. J. Physiol. Cell. Mol. Physiol. 2017, 313, L1006–L1015. [CrossRef]
67. Bellaye, P.-S.; Shimbori, C.; Yanagihara, T.; Carlson, D.; Hughes, P.; Upagupta, C.; Sato, S.; Wheildon, N.;
Haystead, T.; Ask, K.; et al. Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in
lung fibrosis. Eur. Respir. J. 2018, 51, 1700386. [CrossRef]
68. Marinova, M.; Solopov, P.; Dimitropoulou, C.; Biancatelli, R.M.L.C.; Catravas, J.D. Acute exposure of mice to
hydrochloric acid leads to the development of chronic lung injury and pulmonary fibrosis. Inhal. Toxicol.
2019, 31, 147–160. [CrossRef]
69. Solopov, P.; Marinova, M.; Dimitropoulou, C.; Biancatelli, R.M.L.C.; Catravas, J.D. Development of chronic
lung injury and pulmonary fibrosis in mice following acute exposure to nitrogen mustard. Inhal. Toxicol.
2020, 32, 141–154. [CrossRef]
70. Erazo, T.; Moreno, A.; Ruiz-Babot, G.; Rodríguez-Asiain, A.; Morrice, N.A.; Espadamala, J.; Bayascas, J.R.;
Gómez, N.; Lizcano, J.M. Canonical and Kinase Activity-Independent Mechanisms for Extracellular
Signal-Regulated Kinase 5 (ERK5) Nuclear Translocation Require Dissociation of Hsp90 from the ERK5-Cdc37
Complex. Mol. Cell. Boil. 2013, 33, 1671–1686. [CrossRef]
71. Dou, F.; Yuan, L.-D.; Zhu, J.-J.; Wang, K.-Y. Heat Shock Protein 90 Indirectly Regulates ERK Activity by
Affecting Raf Protein Metabolism. Acta Biochim. Biophys. Sin. 2005, 37, 501–505. [CrossRef]
72. Garcia, R.; Merino, D.; Gómez, J.M.; Nistal, J.F.; Hurlé, M.A.; Cortajarena, A.L.; Villar, A.V. Extracellular
heat shock protein 90 binding to TGFβ receptor I participates in TGFβ-mediated collagen production in
myocardial fibroblasts. Cell. Signal. 2016, 28, 1563–1579. [CrossRef] [PubMed]
73. Lee, J.; An, Y.S.; Kim, M.-R.; Kim, Y.-A.; Lee, J.K.; Hwang, C.S.; Chung, E.; Park, I.-C.; Yi, J.Y. Heat Shock
Protein 90 Regulates Subcellular Localization of Smads in Mv1Lu Cells. J. Cell. Biochem. 2015, 117, 230–238.
[CrossRef]
74. Carew, R.M.; Wang, B.; Kantharidis, P. The role of EMT in renal fibrosis. Cell Tissue Res. 2011, 347, 103–116.
[CrossRef] [PubMed]
75. Ashcroft, T.; Simpson, J.M.; Timbrell, V. Simple method of estimating severity of pulmonary fibrosis on a
numerical scale. J. Clin. Pathol. 1988, 41, 467–470. [CrossRef]
76. Wolters, P.J.; Collard, H.R.; Jones, M.G. Pathogenesis of idiopathic pulmonary fibrosis. Annu. Rev. Pathol.
Mech. Dis. 2013, 9, 157–179. [CrossRef]
77. Wong, M.Y.; Doan, N.D.; DiChiara, A.S.; Papa, L.J.; Cheah, J.H.; Soule, C.K.; Watson, N.; Hulleman, J.D.;
Shoulders, M.D. A High-Throughput Assay for Collagen Secretion Suggests an Unanticipated Role for Hsp90
in Collagen Production. Biochemistry 2018, 57, 2814–2827. [CrossRef]
78. Mollapour, M.; Neckers, L. Post-translational modifications of Hsp90 and their contributions to chaperone
regulation. Biochim. Biophys. Acta (BBA) 2012, 1823, 648–655. [CrossRef] [PubMed]
79. Almudéver, P.; Milara, J.; De Diego, A.; Serrano-Mollar, A.; Xaubet, A.; Perez-Vizcaino, F.; Cogolludo, A.;
Cortijo, J. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis.
Thorax 2013, 68, 938–948. [CrossRef]
80. Eroglu, Z.; Chen, Y.A.; Gibney, G.T.; Weber, J.S.; Kudchadkar, R.R.; Khushalani, N.I.; Markowitz, J.; Brohl, A.S.;
Tetteh, L.F.; Ramadan, H.; et al. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
BRAFV600E-Mutant Melanoma. Clin. Cancer Res. 2018, 24, 5516–5524. [CrossRef]
81. Geller, R.; Vignuzzi, M.; Andino, R.; Frydman, J. Evolutionary constraints on chaperone-mediated folding
provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007, 21, 195–205.
[CrossRef] [PubMed]
82. Sharma, K.; Vabulas, R.M.; Macek, B.; Pinkert, S.; Cox, J.; Mann, M.; Hartl, F.-U. Quantitative
Proteomics Reveals That Hsp90 Inhibition Preferentially Targets Kinases and the DNA Damage Response.
Mol. Cell. Proteom. 2011, 11, 111.014654. [CrossRef] [PubMed]
83. Krukenberg, K.A.; Street, T.O.; Lavery, L.A.; Agard, D.A. Conformational dynamics of the molecular
chaperone Hsp90. Q. Rev. Biophys. 2011, 44, 229–255. [CrossRef] [PubMed]
84. Samant, R.S.; Clarke, P.; Workman, P. The expanding proteome of the molecular chaperone HSP90. Cell Cycle
2012, 11, 1301–1308. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 5286 15 of 15
85. Schumacher, J.A.; Crockett, D.K.; Elenitoba-Johnson, K.S.; Lim, M.S. Proteome-wide changes induced by
the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. Proteomics 2007, 7, 2603–2616.
[CrossRef] [PubMed]
86. Song, D.; Chaerkady, R.; Tan, A.-C.; García-García, E.; Nalli, A.; Suarez-Gauthier, A.; Lopez-Rios, F.;
Zhang, X.F.; Solomon, A.; Tong, J.; et al. Antitumor activity and molecular effects of the novel heat shock
protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol. Cancer Ther. 2008, 7, 3275–3284. [CrossRef]
87. Haupt, A.; Joberty, G.; Bantscheff, M.; Fröhlich, H.; Stehr, H.; Schweiger, M.-R.; Fischer, A.; Kerick, M.;
Börno, S.T.; Dahl, A.; et al. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling
components in cancer cells revealed by kinase-targeted chemoproteomics. BMC Cancer 2012, 12, 38. [CrossRef]
88. Oki, Y.; Younes, A.; Knickerbocker, J.; Samaniego, F.; Nastoupil, L.; Hagemeister, F.; Romaguera, J.; Fowler, N.;
Kwak, L.; Westin, J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory
non-Hodgkin lymphoma. Haematologica 2015, 100, e272–e274. [CrossRef]
89. Jensen, M.R.; Schoepfer, J.; Radimerski, T.; Massey, A.J.; Guy, C.T.; Brueggen, J.; Quadt, C.; Buckler, A.;
Cozens, R.; Drysdale, M.J.; et al. NVP-AUY922: A small molecule HSP90 inhibitor with potent antitumor
activity in preclinical breast cancer models. Breast Cancer Res. 2008, 10, R33. [CrossRef]
90. Madala, S.K.; Schmidt, S.; Davidson, C.; Ikegami, M.; Wert, S.; Hardie, J.W. MEK-ERK Pathway Modulation
Ameliorates Pulmonary Fibrosis Associated with Epidermal Growth Factor Receptor Activation. Am. J.
Respir. Cell Mol. Boil. 2012, 46, 380–388. [CrossRef]
91. Chen, Y.; Wang, X.; Cao, C.; Wang, X.; Liang, S.; Peng, C.; Fu, L.; He, G. Inhibition of HSP90 sensitizes a
novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells. Oncotarget 2017, 8, 104193–104205.
[CrossRef] [PubMed]
92. Solopov, P.; Marinova, M.; Dimitropoulou, C.; Catravas, J. Heat Shock Protein (HSP) 90 Inhibitors Prevent
the Development of Nitrogen Mustard-Induced Chronic Lung Injury and Pulmonary Fibrosis in Mice. Am. J.
Respir. Crit. Care Med. 2019, 199, A1021. [CrossRef]
93. Solopov, P.; Biancatelli, R.M.L.C.; Marinova, M.; Dimitropoulou, C.; Catravas, J.D. The HSP90 Inhibitor,
AUY-922, Ameliorates the Development of Nitrogen Mustard-Induced Pulmonary Fibrosis and Lung
Dysfunction in Mice. Int. J. Mol. Sci. 2020, 21, 4740. [CrossRef] [PubMed]
94. Rodina, A.; Wang, T.; Yan, P.; Gomes, E.D.; Dunphy, M.P.S.; Pillarsetty, N.; Koren, J.; Gerecitano, J.F.;
Taldone, T.; Zong, H.; et al. The epichaperome is an integrated chaperome network that facilitates tumour
survival. Nature 2016, 538, 397–401. [CrossRef]
95. Maloney, A.; Clarke, P.A.; Workman, P. Genes and Proteins Governing the Cellular Sensitivity to HSP90
Inhibitors: A Mechanistic Perspective. Curr. Cancer Drug Targets 2003, 3, 331–341. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
E
) ... 
